NovaBay Pharmaceuticals, Inc. (NBY)

1.11 0.02 (1.83%)

As of 2025-12-02 02:02:41 EST

NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis

Traded asNYSE: NBY
ISINUS66987P4090
CIK0001389545
LEI549300D5U7PQPNEX8Q38
EIN680454536
Sector—
IndustryPharmaceutical Preparations
CEO—
Employees—
Fiscal Year End1231
Address2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608
Phone(510) 899-8800
Websitehttp://novabay.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
NBYNovaBay Pharmaceuticals, Inc.2025-12-02 02:02:411.110.021.83
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
NBY0001389545NovaBay Pharmaceuticals, Inc.US66987P4090549300D5U7PQPNEX8Q38680454536NYSE2834Pharmaceutical Preparations1231DE2000 POWELL STREET, SUITE 1150EMERYVILLECA94608UNITED STATESUS(510) 899-88002000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 946082000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608——2000——http://novabay.com2,979,1076,011,000126,010,749NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis2025-11-27 19:05:24
This is a preview of the latest data. Subscribe to access the full data.
NBY Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
NBY Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20242,979,107-71,378-2.33995,816,204-24,281,946-80.6759
20233,050,485-7,825,013-71.950830,098,15027,903,7061,271.5615
202210,875,498-12,801,540-54.06732,194,444-49,223,920-95.7322
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Justin M. HallVP, CEO, Chief Compliance Officer2024350,0000——15,177365,177
Tommy LawTreasurer, CFO2024170,00042,500——7,696220,196
Andrew JonesChief Financial Officer202377,88300—139,078216,961
Audrey KuninChief Product Officer2023170,51300—5,000175,513
Justin M. HallVP, CEO, Chief Compliance Officer2023350,0000——14,146364,146
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202414
202326
202233
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue9,781,00014,726,00014,404,000
Cost Of Revenue3,300,0006,831,0006,623,000
Gross Profit6,481,0007,895,0007,781,000
Research And Development Expenses42,00068,000174,000
General And Administrative Expenses7,379,0006,330,0007,489,000
Operating Expenses12,320,00015,491,00022,198,000
Operating Income-5,839,000-7,596,000-14,417,000
Net Income-7,223,000-9,640,000-10,608,000
Earnings Per Share Basic-2.53-3.96-10.1
Earnings Per Share Diluted———
Weighted Average Shares Outstanding Basic3,396,0004,215,0001,610,000
Weighted Average Shares Outstanding Diluted———
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents430,0003,130,0005,362,000
Marketable Securities Current———
Accounts Receivable194759,000—
Inventories765,0002,877,0003,437,000
Non Trade Receivables———
Other Assets Current110,00081,000113,000
Total Assets Current1,935,0007,154,00011,332,000
Marketable Securities Non Current———
Property Plant And Equipment53,00087,000119,000
Other Assets Non Current480,000497,000489,000
Total Assets Non Current1,488,0001,880,0005,067,000
Total Assets3,423,0009,034,00016,399,000
Accounts Payable623,0001,130,0001,080,000
Deferred Revenue——4,000
Short Term Debt—1,831,0000
Other Liabilities Current1,257,0001,516,0002,724,000
Total Liabilities Current2,843,0004,278,0004,257,000
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current709,0001,442,0001,588,000
Total Liabilities3,552,0005,720,0005,845,000
Common Stock49,000112,000652,000
Retained Earnings-183,457,000-174,849,000-158,152,000
Accumulated Other Comprehensive Income———
Total Shareholders Equity-129,0003,314,00010,554,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization40,00051,000120,000
Share Based Compensation Expense———
Other Non Cash Income Expense———
Change In Accounts Receivable-291,000-1,214,000305,000
Change In Inventories272,000-560,000217,000
Change In Non Trade Receivables———
Change In Other Assets2,00017,0005,000
Change In Accounts Payable-195,000-1,158,000667,000
Change In Other Liabilities———
Cash From Operating Activities-5,183,000-4,131,000-6,654,000
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment6,00019,000112,000
Acquisition Of Business——0
Other Investing Activities———
Cash From Investing Activities1,064,000-19,000-112,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock——0
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities1,500,0001,910,0004,633,000
Change In Cash-2,699,000-2,240,000-2,133,000
Cash At End Of Period430,0003,130,0005,362,000
Income Taxes Paid—359,00024
Interest Paid147,000326,00017,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-2.53-3.96-10.1
Price To Earnings Ratio-0.2375-1.8031-6.7578
Earnings Growth Rate-36.1111-60.79216,633.3333
Price Earnings To Growth Ratio0.00660.0297-0.001
Book Value Per Share-0.0380.78626.5553
Price To Book Ratio-15.82179.081710.412
Ebitda-7,183,000-9,230,000-10,487,976
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures6,00019,00046,000
Free Cash Flow-5,189,000-4,150,000-6,700,000
Return On Equity55.9922-2.9089-1.0051
One Year Beta0.12230.73010.62
Three Year Beta0.54070.63080.5376
Five Year Beta0.51260.7920.7367
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Kazley Michael JohnDirector, Chief Executive Officer, 10% owner2025-10-2156,806,080A56,806,080
R01 Fund LPDirector, Chief Executive Officer, 10% owner2025-10-2156,806,080A56,806,080
Framework Ventures IV L.P.10% owner2025-10-2156,806,080A56,806,080
Lazar David E.10% owner2025-10-16441,325D39,925
R01 Fund LP10% owner2025-10-16220,663A220,663
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Virtu Financial LLC2025-09-3014,00011,0911.2623
MORGAN STANLEY2025-09-30431.3333
BANK OF AMERICA CORP /DE/2025-09-3061481.2708
Tower Research Capital LLC (TRC)2025-09-301,2139481.2795
STATE STREET CORP2025-09-3037,50829,3031.28
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
VANGUARD INDEX FUNDS2025-09-30Institutional Select SharesVSEMX59,24175,828.480.0001
VANGUARD INDEX FUNDS2025-09-30Institutional Plus SharesVEMPX59,24175,828.480.0001
VANGUARD INDEX FUNDS2025-09-30ETF SharesVXF59,24175,828.480.0001
VANGUARD INDEX FUNDS2025-09-30Institutional SharesVIEIX59,24175,828.480.0001
VANGUARD INDEX FUNDS2025-09-30Admiral SharesVEXAX59,24175,828.480.0001
This is a preview of the latest data. Subscribe to access the full data.